NHS Wegovy Tablet Waitlist UK: When Will It Be Available for Free?

# NHS Wegovy Tablet Waitlist UK: When Will It Be Available for Free?

Oral Wegovy received MHRA approval on 11 June 2026. It is not on the NHS. It will not be on the NHS for a meaningful period of time. This guide explains why, gives you a realistic timeline for when NHS access might become available, describes what NHS weight loss medication access actually looks like right now, and helps you think through your options in the meantime.

This is a guide for people who want to access oral Wegovy but cannot afford private prescription prices. It does not minimise that constraint — private prescription costs of £64–£113 per month are a real barrier — but it gives you accurate information about what is and is not available, so you can make the best decision for your situation.

> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment.

—

## Current situation: June 2026

Oral Wegovy (semaglutide tablet) received marketing authorisation from the MHRA on 11 June 2026. This means it is now a legally licensed medicine in the UK and can be prescribed by registered UK prescribers for appropriate patients. However, MHRA licensing and NHS availability are entirely separate things.

The National Institute for Health and Care Excellence (NICE) has not commenced a technology appraisal of oral semaglutide for weight management. NICE is the body that evaluates medicines and decides whether they should be recommended for NHS use in England. Scotland (SMC), Wales (AWMSG), and Northern Ireland (NICER) have their own equivalent bodies and processes. Until NICE issues a positive recommendation, NHS commissioning bodies will not routinely fund oral Wegovy — even for patients who meet the eligibility criteria.

There is no official NHS waitlist for oral Wegovy. There is no mechanism to join one. NHS GPs cannot currently prescribe oral Wegovy on an NHS prescription.

—

## Why it is not on the NHS yet

The pathway from MHRA approval to NHS availability involves a separate, lengthy evaluation process. NICE must independently assess the clinical evidence (which NICE reviews itself rather than simply accepting MHRA’s findings), model the cost-effectiveness of the medicine versus existing treatments and doing nothing, determine the appropriate patient population for NHS use, and negotiate with the manufacturer on NHS pricing (which is always lower than the private market price).

This process typically takes 18 to 24 months from marketing authorisation for a new medicine. The NICE evaluation of injectable Wegovy took approximately 20 months from MHRA approval to first NICE recommendation. Oral semaglutide is a new formulation of the same ingredient, so NICE may have a faster evidence review — but the cost-effectiveness modelling and commissioning guidance still require substantial time.

There is also a budget constraint that shapes NHS decisions on GLP-1 drugs specifically. The NHS is currently managing the phased rollout of injectable Wegovy through specialist weight management services, a process that is already capacity-constrained. The addition of a new oral formulation creates additional demand that the NHS must plan for carefully. NICE’s evaluation will include an assessment of the affordability to the NHS as a whole, not just the cost per individual patient.

—

## Realistic timeline for NHS access

Based on the standard NICE evaluation timeline and the current status (MHRA approval June 2026, NICE evaluation not yet started), a realistic assessment is as follows.

NICE would need to start the scoping and assessment process, typically around three to six months after marketing authorisation — so late 2026 or early 2027. The full evaluation, including public consultation periods, evidence review, and committee meetings, takes 12 to 18 months from commencement. This puts a first NICE guidance publication at late 2027 to mid-2028 at the earliest.

Even after positive NICE guidance, NHS commissioning and formulary inclusion takes additional time — typically three to six months before prescribers can routinely access the medicine on the NHS. Realistic widespread NHS access for eligible patients: 2028 to 2029.

This is not a pessimistic forecast — it is what the standard NHS approval pathway looks like for a newly licensed medicine. It is possible that NICE moves faster if it treats oral semaglutide as a variation of already-evaluated injectable semaglutide. It is also possible that NHS budget pressures slow the process further. Neither acceleration nor delay can be reliably predicted.

—

## What NHS weight loss medication access actually looks like now

Understanding what is currently available on the NHS for weight management helps put the oral Wegovy gap in context.

Injectable Wegovy (2.4mg subcutaneous weekly injection) received NICE recommendation for NHS use in 2023, with commissioning phased in from 2024. However, NHS access is restricted far more tightly than private access. The current NHS criteria require: referral to a specialist NHS Tier 3 or Tier 4 weight management service, a BMI of 40 kg/m² or higher (or 35 kg/m² or higher with a significant weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea), and treatment is limited to a maximum of two years. These criteria are considerably more restrictive than the private prescription eligibility (BMI 30+, or 27+ with comorbidity).

Orlistat, an older weight loss medication, is available on NHS prescription for appropriate patients and is significantly less effective than semaglutide. It is a lipase inhibitor that reduces fat absorption and requires a very low-fat diet to avoid unpleasant GI side effects. It is not a GLP-1 agonist and does not have semaglutide’s appetite-suppressive properties.

Mounjaro (tirzepatide injection) received NHS approval in early 2025 and is being phased in through specialist services under similar criteria to injectable Wegovy. It is a dual GIP/GLP-1 receptor agonist with somewhat superior weight loss outcomes to injectable semaglutide in head-to-head trials.

—

## The cost of waiting versus proceeding privately

For people who meet the eligibility criteria for oral Wegovy but cannot access it on the NHS, the decision is whether to wait for NHS access or proceed with private prescription.

At the cheapest UK provider (Bolt Pharmacy at £64 per month), two years of private treatment would cost approximately £1,536. At the mid-range of the current market (approximately £85–£90 per month), two years would cost approximately £2,040–£2,160. These are meaningful sums, but they are not necessarily unaffordable relative to the health benefits for patients who qualify on clinical grounds.

The health economics of GLP-1 treatment for obesity are substantially positive — the reduction in cardiovascular events, type 2 diabetes incidence, hypertension management costs, sleep apnoea treatment needs, and joint replacement requirements all offset a significant proportion of the medication cost at a population level. This is precisely the cost-effectiveness argument NICE will evaluate, and it is likely to support a positive recommendation when that evaluation completes.

For some patients, delaying two years while waiting for NHS access carries its own costs — in health terms, in quality of life, and in progression of weight-related comorbidities. This is a clinical and personal decision that you should discuss with your GP or a weight management specialist.

—

## What to do right now

There are several constructive steps to take while waiting for NHS oral Wegovy access. First, register with your GP and flag your interest in weight management treatment. A GP referral to a Tier 3 weight management service may be available and is the pathway to NHS injectable Wegovy, which is the same active ingredient. Second, check your eligibility for NHS injectable Wegovy — the criteria are more restrictive, but many people who qualify for oral Wegovy privately will also qualify for injectable Wegovy through NHS services.

Third, if you are considering private treatment, use this site to compare provider prices accurately. The difference between the cheapest and most expensive providers in the UK is currently £50 per month — nearly £600 per year — for identical medication. Choosing the right provider matters financially.

Fourth, stay informed. The NHS landscape for GLP-1 drugs is changing rapidly. Bookmark this site’s NHS availability guide and the NICE website for updates. When NICE commences the oral semaglutide appraisal, that will be a public process with a predicted publication date.

—

## Frequently asked questions

### Will the NHS ever cover Wegovy tablets?

Almost certainly yes, eventually — the clinical evidence for oral semaglutide is strong, and NICE has already recommended injectable semaglutide for NHS use. The question is when, not whether. Based on the standard NICE evaluation timeline, the earliest realistic date for NHS commissioning of oral Wegovy is 2028.

### Can my GP prescribe Wegovy tablets privately?

Yes. Any registered UK prescriber can issue a private prescription for oral Wegovy for patients who meet the MHRA-licensed eligibility criteria. Private prescriptions are not NHS-funded, so the cost falls to the patient. Some GP practices do not offer private prescribing — in these cases, online weight management clinics and private pharmacies provide the same service.

### Is there any free access to oral Wegovy anywhere in the UK?

Not currently. No NHS service or charitable programme is currently providing oral Wegovy to patients without cost. The only current route to oral Wegovy is a private prescription. Access to injectable semaglutide on the NHS through specialist weight management services remains the only free-at-point-of-use semaglutide option, and only for those who meet the more restrictive NHS criteria.

### What is the difference between NHS Wegovy injection and the tablet?

Both contain the active ingredient semaglutide. The injection (Wegovy 2.4mg weekly) is administered subcutaneously once a week and is available through NHS specialist weight management services for patients with BMI 40+ (or 35+ with significant comorbidities). The tablet (oral Wegovy, 1.5mg–25mg daily) is not currently available on the NHS and requires a private prescription. The clinical efficacy at maximum dose is broadly comparable across the two formulations.

### Can I access oral Wegovy through a clinical trial?

It is worth checking the NIHR (National Institute for Health Research) clinical trials register and the ClinicalTrials.gov database for ongoing UK trials of oral semaglutide. Trial participation provides access to the medication at no cost but is not guaranteed and involves additional clinical commitments. Eligibility criteria for trials are typically different from (and often more restrictive than) the licensed indication.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets (oral semaglutide) are a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*